Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 3/20 | 0.54 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | MMP8 | P22894 | 2/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 5/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14010459 | 1.00 | MMP12 (0.54) | MMP12MMP2MMP8MMP13CNR2 | |
| SCHEMBL3341734 | 0.98 | MMP12 (0.53) | MMP12MMP2MMP8MMP13CNR2 | |
| SCHEMBL26109837 | 0.91 | CNR2 (0.53) | CNR2PTPN1MEN1KMT2AHDAC8 | |
| SCHEMBL26109839 | 0.91 | CNR2 (0.53) | CNR2PTPN1MEN1KMT2AHDAC8 | |
| SCHEMBL27694707 | 0.88 | NAALAD2 (0.66) | CNR2NAALAD2MEN1KMT2AHDAC8 | |
| SCHEMBL6567538 | 0.88 | NAALAD2 (0.66) | CNR2NAALAD2MEN1KMT2AHDAC8 | |
| SCHEMBL6567542 | 0.88 | NAALAD2 (0.66) | CNR2NAALAD2MEN1KMT2AHDAC8 | |
| SCHEMBL20549139 | 0.87 | CNR2 (0.49) | MMP12MMP2MMP8MMP13CNR2 | |
| SCHEMBL31499163 | 0.87 | NAALAD2 (0.58) | MMP2CNR2NAALAD2MEN1KMT2A | |
| SCHEMBL3341731 | 0.87 | CNR2 (0.49) | MMP12MMP2MMP8MMP13CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1855665-B1 | USE OF PHENYLACETYL-DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT TO TREAT VON HIPPEL-LINDAU (VHL) DISEASE | BURZYNSKI STANISLAW R (US) | 2008-12-31 | — | — | EP | claimed |
| US-7427619-B2 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy | BURZYNSKI STANISLAW R | 2008-09-23 | — | — | US | claimed |
| CN-100400039-C | Composition for treating tumor diseases and application thereof | BURZYNSKI STANISLAW R (US) | 2008-07-09 | — | — | CN | claimed |
| EP-1855665-A1 | USE OF PHENYLACETYL-DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT TO TREAT VON HIPPEL-LINDAU (VHL) DISEASE | BURZYNSKI, Stanislaw R. (US) | 2007-11-21 | — | — | EP | claimed |
| US-20060246016-A1 | Toothpaste containing anticancer agents | BURZYNSKI STANISLAW R | 2006-11-02 | — | — | US | claimed |
| WO-2006096481-A1 | USE OF PHENYLACETYL-DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT TO TREAT VON HIPPEL-LINDAU (VHL) DISEASE | BURZYNSKI STANISLAW R (US) | 2006-09-14 | — | — | WO | claimed |
| US-20060205818-A1 | Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives | BURZYNSKI STANISLAW R | 2006-09-14 | — | — | US | claimed |
| US-6987131-B1 | Phenylacetic acid compositions for treating or preventing hypercholesterolemia | BURZYNSKI STANISLAW R | 2006-01-17 | — | — | US | claimed |
| US-6943192-B2 | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate | BURZYNSKI STANISLAW R (US) | 2005-09-13 | — | — | US | claimed |
| CN-1660061-A | Composition for treating tumor diseases and application thereof | BURZYNSKI STANISLAW R (US) | 2005-08-31 | — | — | CN | claimed |
| EP-1098643-B1 | PHENYLACETYLGLUTAMINE, PHENYLACETYLISOGLUTAMINE, AND/OR PHENYLACETATE FOR THE TREATMENT OF NEOPLASTIC DISEASES | BURZYNSKI STANISLAW R (US) | 2004-01-07 | — | — | EP | claimed |
| US-20010044466-A1 | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate | BURZYNSKI STANISLAW R (US) | 2001-11-22 | — | — | US | claimed |
| CN-1319010-A | Therapeutic methods for administering phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate | BURZYNSKI STANISLAW R (US) | 2001-10-24 | — | — | CN | claimed |
| US-6258849-B1 | DRUG COMPOSITION WITH CARBOXYALKYL DIAMIDES WITH PHENYL OR NAPHTHYL GROUPS | BURZYNSKI STANISLAW R (US) | 2001-07-10 | — | — | US | claimed |
| EP-1098643-A2 | TREATMENT REGIMEN FOR ADMINISTRATION OF PHENYLACETYLGLUTAMINE, PHENYLACETYLISOGLUTAMINE, AND/OR PHENYLACETATE | BURZYNSKI, Stanislaw R. (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004894-A2 | TREATMENT REGIMEN FOR ADMINISTRATION OF PHENYLACETYLGLUTAMINE, PHENYLACETYLISOGLUTAMINE, AND/OR PHENYLACETATE | BURZYNSKI STANISLAW R (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0500905-B1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING AIDS | BURZYNSKI STANISLAW R (US) | 1996-03-13 | — | — | EP | claimed |
| US-5254587-A | Methods for treating AIDS | BURZYNSKI STANISLAW R (US) | 1993-10-19 | — | — | US | claimed |
| EP-0500905-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING AIDS. | BURZYNSKI STANISLAW R (US) | 1992-09-02 | — | — | EP | claimed |
| WO-1992004027-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING AIDS | BURZYNSKI STANISLAW R (US) | 1992-03-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044466-A1 | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate | ACACA, PGAM1, GOT1 | MMP12 3124/4885MMP2 1555/4885MMP8 2767/4885 |
| US-20060205818-A1 | Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives | VHL, FH, HTT | MMP12 2427/4885MMP2 1371/4885MMP8 3341/4885 |
| US-20060246016-A1 | Toothpaste containing anticancer agents | HDAC10, TAS2R10, TAS2R30 | MMP12 685/4885MMP2 795/4885MMP8 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.